Literature DB >> 19017707

Specific antibodies to diisocyanate and work-related respiratory symptoms in apprentice car-painters.

M Dragos1, M Jones, J-L Malo, H Ghezzo, D Gautrin.   

Abstract

BACKGROUND: Isocyanates are the main cause of occupational asthma in most countries. Study of immunological markers of diisocyanate asthma may identify individuals at risk.
OBJECTIVES: (1) To study changes in specific antibodies to hexamethylene diisocyanates (HDI); (2) to describe the incidence of work-related respiratory symptoms in relation to changes in specific antibody levels.
METHODS: Prospective study in 385 apprentice car-painters during their 18 months of training. Participants were assessed on entering and completing their training using questionnaires, methacholine challenges and measurements of HDI-specific immunoglobulin E (IgE), immunoglobulin G (IgG) and subclass 4 of IgG (IgG4) antibodies.
RESULTS: Complete data are available for 298 subjects. 13 subjects (4.4%) reported >or=1 new work-related lower respiratory symptoms and 19 (6.4%), >or=1 new work-related nasal symptoms. Increases in levels of specific IgE and IgG above the 97th and 95th percentiles were significantly associated with duration of exposure. Increase in specific IgG was inversely related to incidence of work-related lower respiratory symptoms (OR = 0.001, 95% CI 0.000 to 0.09) after adjusting for relevant covariates. The rise in specific IgG4 was significantly greater in those who did not develop work-related nasal symptoms (OR = 0.09, 95% CI 0.01 to 0.7).
CONCLUSION: In this cohort of apprentice car-painters, a small proportion show increases in HDI-specific IgG and IgE after few months of exposure. Increases in specific IgG and IgG4 appear to have a protective effect on the incidence of work-related lower and upper respiratory symptoms, respectively. Assessment of specific antibodies to isocyanates may help identify subjects at risk of developing symptoms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19017707     DOI: 10.1136/oem.2007.038125

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  7 in total

Review 1.  Diagnosis of occupational asthma: an update.

Authors:  Edgardo J Jares; Carlos E Baena-Cagnani; R Maximiliano Gómez
Journal:  Curr Allergy Asthma Rep       Date:  2012-06       Impact factor: 4.806

Review 2.  Risk factors, predictors, and markers for work-related asthma and rhinitis.

Authors:  Denyse Gautrin; Jean-Luc Malo
Journal:  Curr Allergy Asthma Rep       Date:  2010-09       Impact factor: 4.806

Review 3.  Occupational rhinitis and asthma: where do we stand, where do we go?

Authors:  Roberto Castano; Jean-Luc Malo
Journal:  Curr Allergy Asthma Rep       Date:  2010-03       Impact factor: 4.806

4.  CTNNA3 (α-catenin) gene variants are associated with diisocyanate asthma: a replication study in a Caucasian worker population.

Authors:  David I Bernstein; Michael Kashon; Zana L Lummus; Victor J Johnson; Kara Fluharty; Denyse Gautrin; Jean-Luc Malo; André Cartier; Louis-Philippe Boulet; Joaquin Sastre; Santiago Quirce; Dori Germolec; Susan M Tarlo; Maria-Jesus Cruz; Xavier Munoz; Michael I Luster; Berran Yucesoy
Journal:  Toxicol Sci       Date:  2012-09-13       Impact factor: 4.849

5.  Inhalation of ortho-phthalaldehyde vapor causes respiratory sensitization in mice.

Authors:  Victor J Johnson; Jeffrey S Reynolds; Wei Wang; Kara Fluharty; Berran Yucesoy
Journal:  J Allergy (Cairo)       Date:  2011-07-14

Review 6.  Environmental isocyanate-induced asthma: morphologic and pathogenetic aspects of an increasing occupational disease.

Authors:  Annette Fisseler-Eckhoff; Holger Bartsch; Rica Zinsky; Joachim Schirren
Journal:  Int J Environ Res Public Health       Date:  2011-09-09       Impact factor: 3.390

7.  Occupational airborne exposure, specific sensitization and the atopic status: evidence of a complex interrelationship.

Authors:  Xaver Baur; Liubov Barbinova
Journal:  J Occup Med Toxicol       Date:  2013-02-13       Impact factor: 2.646

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.